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Abstract
Recent investigations in mice revealed that natural immunologlcal tolerance to endogenous minor
lymphocyte-stimulating locus 1 a (Mls-1») antigen correlates primarily with deletion of Mls-1 •-
speciflc V36+ T lymphocytes In the thymus. Similar mechanisms account for acquired tolerance
in some Instances since the neonatal injection of Mls-1 "-expressing MHC compatible cells in
neonatal mice within the first 24 h of life causes clonal deletion of V36+ T cells. Here we
demonstrate that V^6+ T cells are not deleted In mice neonatally treated with Mls-1* spleen cells
expressing allogenelc H-2 molecules. However, when such non-deleted Ve6+ T cells were tested
In vitro, no interleukln 2 (IL-2) secretion or proliferation was observed after Mls-1* stimulation.
This non-responsive state could be overcome by addition of exogenous IL-2, consistent with the
fact that Vp6+ cells enlarged and expressed IL-2 receptors upon Mls-1 ° stimulation. Furthermore,
the same neonatally treated mice showed In vitro functional unresponsiveness of cytotoxic T
cells but not of IL-2-secreting cells specific for the tolerated allogeneic MHC antigens. Taken
together, our data Indicate that neonatal tolerance to Mls-1* can be accomplished by either clonal
deletion or clonal anergy, and that it does not necessarily correlate with tolerance to MHC
determinants.
Introduction
Antigen-specific lymphocytes capable of responding to
pathogens must simultaneously be unresponsive to self antigens.
Tolerization of T cell precursors may take place by their physical
elimination during differentiation in the thymus (1). Although clonal
deletion has been well described in both normal (2-4) and
transgenic (5 - 8) mouse models, it is conceivable that alternative
tolerizing mechanisms exist. Possible mechanisms include clonal
mactivation or anergy, suppression, and lack of induction of
autoantigen specific T cells because self determinants are
expressed in anatomically 'privileged sites' or because they are
expressed only on non-lymphoid cells that are incapable of
effective antigen presentation. Recently, in vitro clonal anergy
has been characterized in detail for certain antigen-specific T cell
clones (9 -11) as well as for T cells obtained from normal (12-16)
or transgenic (17-20) mice. However, it is not clear whether
'anergic' T lymphocytes exist in vivo and how this functional
anergy is regulated.
The minor lymphocyte-stimulating 1a (Mls-1a) antigen
(21 -24), although molecularly not defined, provides a useful
model system for studying self tolerance. Because Mls-1a-
specific T cells express particular TCR Vfl domains such as Vp6
(3), V (25), Vp8.1 (4), and V ^ (26), their fate can be followed
by serological means using vyspecific monoclonal antibodies.
In Mls-1b mice, Mls-1 "-specific Vj6+ cells range between 4 and
15% of the total T cell pool, whereas most Mls-1a mice show
< 1 % Vp6+ cells due to clonal deletion. Interestingly, recent
studies in immunized (13) and chimeric (12,14-16) mice have
shown that Vff6+ cells need not be deleted to achieve
unresponsiveness to Mls-1a in vitro. Instead, VP6+ cells were
functionally unresponsive, indicating that clonal inactivation or
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anergy was an alternative means for maintaining tolerance to
Mls-1a.
Ever since Bilhngham et al. initially showed that the injection
of allogeneic cells into a newborn mouse induces specific
immunological tolerance for the donor's tissues and organs (27),
this approach has been widely used to study antigen-specific
immunological unresponsiveness. It was reasoned that neonatal
mice may recognize foreign molecules as 'self because of the
immaturity of their immune systems. Accordingly, we recently
demonstrated that Mls-1b mice clonally deleted their V^6+ T
cells after neonatal injection of Mls-1a spleen cells (28), thus
exhibiting a phenotype of acquired tolerance similar to natural
tolerance to self Mls-1a.
In this study we show that deletion of V ^ * cells occurred only
when the Mls-1a spleen cells injected were mouse MHC (H-2)
compatible with the newborn Mls-1b mouse. In contrast, when
H-2-incompatible Mls-1a spleen cells were inoculated, practically
no or only limited deletion of V ^ * T cells was found. Never-
theless, functional unresponsiveness to Mls-1a in vitro was
detected, indicating that the VP6+ cells present in mice
neonatally treated with H-2-incompatible spleen cells were
anergic. Possible mechanisms involved in deletion or anergy of
Mls-1a-specific cells depending upon MHC compatibility of
neonatally injected cells are discussed.
Methods
Animals
Inbred DBA/2 ( H - ^ , BALB/c (H-2"), B10 D2 (H-2d), B10.BR
(H-211), and C57BL/6 (H-213) mice were purchased from the
Institut fur Zuchthygiene, Tierspital, University of Zurich,
Switzerland. B10.G (H-201) and DBA/1 (H-2") mice were obtained
from Olac, Bicester, Oxon, UK. BALB.D2-MIS8 (29) breeders
were kindly provided by Dr Hilliard Festenstein, London Hospital
Medical College, UK. BALB.D2-Mlsa (also referred to as
BALB.D2) and hybrid F, mice were bred locally. Characteristics
of these strains relevant to the present study are summarized
in Table 1.
Neonatal tolerization
Spleen cells (10s) from untreated donor mice were washed and
injected i.p. in 100 y.\ Hank's balanced salt solution within 24 h
of birth.
Cytofluorographic analysis
Aliquots of thymocytes or lymph node cells were stained at 4°C
with rat mAb 44-22-1 (V^6-specific) (30) or KJ16-133
(V^. I /V08.2-specific) (4) followed by fluorescein isothiocyanate-
conjugated goat anti-rat IgG (Tago Inc., Burlingame, CA). The
PE-conjugated, CD4-specific mAb GK 1.5 (31) (Becton-
Dickinson, Mountain View, CA) was used for double staining. To
assess the chimerism of neonatally transfused mice, haplotype-
specific mouse lgG2a mAbs K7-309 (Kb-specific) (32) or 34-2-12
(Dd-specific) (33) was used followed by a fluorescent goat-anti
mouse lgG2a reagent (Southern Biotechnology Associates Inc.,
Birmingham, AL). Viable cells (10,000 per sample) were analyzed
by flow cytometry on a Epics Profile Analyzer (Coulter Electronics
Inc., Hialeah, FL) with logarithmic scales. Percentages after
subtraction of backgrounds (0.0-1.4%) obtained with the
fluorescein conjugate alone are indicated.
Mixed lymphocyte reactions
Responder lymphocytes (3 x 106) were incubated with
irradiated (1000 rad) anti-Thy-1.2 mAb (AT-83) (34) plus rabbit
complement-treated splenic stimulator cells (5 x 106) in 2 ml
Iscove's modified Dulbecco's medium supplemented with 19 mM
L-glutamme, 105 U/l penicillin-streptomycin solution,
5 x 10~5 M 2-mercaptoethand, and 10% heat-inactivated FCS
in 24-well plates at 37°C in 5% CO2 plus air. Cultures used for
the assessment of [3H]thymidine uptake and interleukin 2 (IL-2)
secretion contained 5 x 105 responder cells and 1-10 x 10s
stimulator cells in 96-well flat-bottomed plates. As controls,
responder cells and stimulator cells respectively were cultured
alone, in the presence of concanavalin A (5 fig/ml), or together
with the Mls-1 "-specific T cell hybrid RG17.16 (22). In cultures
with exogenous IL-2 either human recombinant (r)IL-2 (200 U/ml;
corresponding to 60 ng/ml) or 10% supernatant of concanavalin
A-stimulated rat spleen cells was added.
IL-2 measurement
II-2 contents of 48 h mixed lymphocyte reaction (MLR)
supernatants were assayed on CTLL-2 cells (35) as described
(36). IL-2 values were calculated using OD 405 nm
measurements after background subtraction, rlL-2 was used to
calibrate a standard curve where 50% of the maximal OD 405 nm
value was arbitrarily defined as 100 U of IL-2/ml. Consequently,
IL-2 values were calculated as follows: (Dilution factor of sample
supernatant at 50% max. OD) •+• (Dilution factor at 50% max.
OD of rlL-2 standard) x 100 U/ml. In representative control
experiments growth of CTLL-2 cells in MLR supernatants was
always completely blocked by the IL-2-specific mAb S4B6,
proving that the only factor measured was IL-2 (some CTLL-2
cells also show a minor sensitivity to IL-4).
51Cr release assay
Mice were killed and responder spleen cells stimulated in mixed
lymphocyte cultures with irradiated (2000 rad) stimulator spleen
cells at a ratio of 4 x '\0BA x 106 cells in 24-well plates. After
5 days effector cells were harvested and tested for cytotoxic
activity on 51Cr-labeled target fibroblasts as described in detail
elsewhere (37,38). MC57G (H-2d), D2 (H-2C)), or DBA/1 (H-2«)
target cells (established methylcholanthrene induced or SV40
transformed murine cell lines) were placed (1 Orwell) in round-
bottomed microtiter plates (Flacon Labware, Division of Becton-
Dickinson, Oxnard, CA) and co-incubated with titrated effector
cells for 4.5 h.
Results
Mls-1b mice neonatally treated with H-2-compatible but not
those treated with H-2-incompatible Mls-1" spleen cells deleted
Vfi* T cells
In this study we compared two different regimes for neonatal
tolerance induction. The first was the injection of spleen cells
which only express H-2 molecules compatible with the recipient's
MHC (referred to as 'H-2-compatible cells'); the second was the
injection of spleen cells expressing foreign MHC molecules
(referred to as 'H-2 incompatible cells'). Newborn BALB/c
(H-2d/Mls-1b) mice were treated i.p. with spleen cells from the
various donor strains within 24 h of birth. Two to six weeks later,
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cortisone-resistant thymocytes were analyzed by flow
cytofluorometry. As expected, injection of syngeneic (Mls-1")
spleen cells did not affect V ^ expression (Table 2A). However,
as described earlier (28), strongly reduced Vp6 percentages
were observed when the spleen cells injected were from DBA/2
(H-2d/Mls-1a) mice. Efficient deletion of Vp6+ cells was also
found in BALB/c mice neonatally treated with Mls-1a spleen cells
from H-2dxd F, mice [i.e. from (BALB/c x DBA/2)F, or from
(BALB/c x BALB.D2-Mlsa)F1 respectively]. Furthermore,
comparable deletion of V36+ cells occurred when
(BALB/c x B10.G)F, (H-2*^ mice were neonatally transfused
from Mls-1a spleen cells from H-2-compatible (B10.D2 x
DBA/1 )F, mice or from (BALB/c x DBA/2)F1 (H-2dxd) mice.
Concerning the latter combination, earlier studies (39) had shown
that Mls-1a spleen cells from donors not tolerant to MHC deter-
minants of the neonatal host were capable of inducing clonal
deletion of V^6+ cells despite overt graft versus host disease.
Finally, control treatment with syngeneic Mls-1b spleen cells did
Table 1. Characteristics of mouse strains used in this study
Mouse strain
BALB/c
B10.D2
BALB.D2-Mlsa(BALB.D2)
DBA/2
C57BL/6
B10G
DBA/1
B10BR
(C57BL/6 x BALB/c)F,
(C57BU6 x DBA/2)F,
(BALB/c x B10G)F,
(BALB/c x DBA/1 )F,
Mls-1
b
b
a
a
b
b
a
b
b/b
b/a
b/b
b/a
H-2
d
d
d
d
b
q
q
k
b/d
b/d
d/q
d/q
%V06+/CD4 +
124
9.3
0.4
0.4
7.4
3.8
4.2
8.8
12.0
0.5
11.3
0.7
Lymph node cells were analyzed by two-color immunofluorescence. Data
(means of three individual mice; SEM < 0.8) represent <W/J6+ cells of
the total CD4+ population, calculated as follows: (%Vp6+CD4 +
+ %CD4+) x 100.
not alter Vp6 expression significantly when compared to
untreated controls (Tables 1 and 2A).
We next injected H-2-incompatible spleen cells and made the
following surprising observation: the injection of Mls-1a spleen
cells from fully allogeneic DBA/1 (H-201) mice or from F, mice
heterozygous at the H-2 locus did not induce elimination of
Vp6+ lymphocytes. For example, BALB/c mice neonatally
treated with (BALB/c x DBA/1 )F, or (DBA/2 x DBA/1 )F, (both
HB-2dX(VMIs-1a) spleen cells exhibited 9.7 or 8 .1% Vg6 +
lymphocytes respectively. Newborn (BALB/c x B10.G)F, mice
which received H-2-semi-allogeneic (B10.BR x DBA/1 )F,
(H-2kxq) spleen cells showed some deletion but still had quite
high percentages (6.0%) of V^6+ mature thymocytes. Thus,
Mls-1b mice neonatally treated with H-2-(semi)allogeneic Mls-1a
spleen cells showed much impaired deletion of Vg6+ cells. As
positive controls, normal lymphocyte maturation in the mice
studied was documented by stainings with monoclonal antibody
KJ16-133, specific for a population of lymphocytes which
developed largely (but not entirely) independently of Mls-1a.
Similar analyses were performed by injection of H-2bxd F,
spleen cells in neonatal C57/BL/6 (H-25) or BALB/c (H-201) mice,
respectively. Expression of V36 and Vj8 by CD4 + CD8~
thymocytes or lymph node cells are shown in Table 3. In parallel
to the findings described above, C57BL/6 or BALB/c mice (both
Mls-1 ^ treated with H-2-incompatible Mls-1a spleen cells from
(C57BL/6 x DBA/2)F, mice showed practically no or only
partially reduced percentages of Vg6+ cells when compared to
controls transfused with Mls-1b F, spleen cells (Table 3B).
Furthermore, lymph node cells from BALB/c mice treated with
Mls-1a F, or Mls-1b F, spleen cells, respectively, did not differ
significantly in V^6 fluorescence intensity, suggesting that their
TCRs were not specifically down-regulated in response to
Mls-1a.
Since tolerogen-specific lymphocytes showed reduced levels
of accessory molecules in some systems (40), the expression of
CD4 on peripheral T cells was analyzed. No decrease in either
the number of CD4+ cells or the surface density of CD4
Table 2. Expression of Vp6 and V^8 in mice neonatally treated with H-2d/q spleen cells
Neonatally treated mice
Recipient
(all Mls-1 ^
(A) Mice treated with
BALB/c
BALB/c
BALB/c
BALB/c
(BALB/c x B10.GJF,
(BALB/c x B10G)F,
(BALB/c x B10.G)F,
(B) Mice treated with
BALB/c
BALB/c
BALB/c
(BALB/c x B10.G)F,
Cells injected (Mls-1)
H-2-compatible spleen cells
BALB/c (b)
DBA/2 (a)
(BALB/c x DBA/2)F1 (b/a)
(BALB/c x BALB.D2JF, (b/a)
(BALB/c x B10.G)F, (b/b)
(B10.D2 x DBA/1)F, (b/a)
(BALB/c x DBA/2)F, (b/a)
H-2-incompatible spleen cells
DBA/1 (a)
(DBA/2 x DBA/1 )F, (a/a)
(BALB/c x DBA/1 )F, (b/a)
(B10.BR x DBA/1)F, (b/a)
No. of mice
3
3
3
3
2
3
3
3
2
3
3
% positive cortisone-resistant
Vfl6
12.0 ± 0.6
1.0 ± 0.3
1.7 ± 0.8
0.8 ± 0.7
9.8 ± 1.3
2.6 ± 0.7
0.8 ± 0.8
12.4 ± 0.3
8.1 ± 1.1
9.7 ± 0.9
6.0 ± 1.2
thymocytes
21.1 ± 0.7
18.0 ± 0.9
19.4 ± 1.1
17.6 ± 1.1
17.7 ± 1.3
16.5 ± 0.9
17.8 ± 2.9
19.3 ± 1.0
18.8 ± 1.4
19.9 ± 0.1
16.8 ± 1.6
Mice were treated with 10s spleen cells i.p. within 24 h of birth and assayed after 2 - 6 weeks. Indirect immunofluorescence with mAbs 44-22-1
(Vp6-specific) or KJ 16-133 (Vp8-specific) was performed. The values represent mean ± SEM of cortisone-resistant thymocytes (obtained 48 h after a
single i.p. injection of 4 mg hydrocortisone acetate).
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Table 3. Expression of V ^ and V ^ in mice neonatally treated with H-2*b spleen cells
Neonatally treated mice
Recipient
(all Mls-1")
Cells injected
(Mls-1)
No. of mice Tissue % positive lymphocytes
V/S8/CD4
(A) Mice treated with H-2-compatibie spleen cells
(C57BL/6 x BALB/c)F,
(C57BL/6 x BALB/c)F,
BALB/c
(C57BL/6 x BALB/c)F,
(b/b)
(C57BU6 x DBA/2)F,
(b/a)
DBA/2
(a)
(B) Mice treated with H-2-incompatible spleen cells
C57BL/6 (C57BL/6 x BALB/c)F,
(b/b)
C57BU6 (C57BU6 x DBA/2)F,
(b/a)
BALB/c (C57BL/6 x BALB/c)F,
(b/b)
BALB/c (C57BU6 x DBA/2)F,
(b/a)
3
5
3
3
3
8
11
thymus
lymph node
thymus
lymph node
thymus
lymph node
thymus
lymph node
thymus
lymph node
thymus
lymph node
thymus
lymph node
8.7
12.0
0.8
0.9
0.8
0.9
7.9
8.4
6.5
8.2
6.1
12.5
4.7
8.9
±
±
±
±
±
±
±
±
±
±
±
±
±
±
1 0
0 6
0.0
0.4
0.2
0.1
1.2
1.0
0.7
0.6
0.7
0.8
0.9
07
13.5
16.2
11.7
12.7
14.3
15.9
14.3
15.5
14.4
14.8
13.1
178
13.1
16.9
±
±
±
±
±
±
±
±
±
±
±
±
±
±
0.8
0.1
1.4
0.5
2.0
1.3
1.7
1.4
1.0
1.6
1.2
05
0.5
0.5
Mice were treated with 10s spleen cells i.p. within 24 h of birth and assayed after 2 - 6 weeks. Thymocytes treated with CD8-specific rat IgM mAb
3.168.1 plus complement or untreated lymph node cells were stained with mAbs 44-22-1 (Vp6-specific) or KJ16-133 (V^8-specific), respectively, plus
a CD4-specific mAb. Data are mean ± SEM and represent percentages of the total CD4+ population. Chimensm determined with MHC class l-specific
mAbs in mice treated with H-2-incompalible cells was as follows: immunofluorescence on lymph node cells stained with donor MHC-speafic mAb revealed
mean values per group between 7.6 and 10.5% positive cells (SEM < 5.0), those stained with host MHC-specific mAb revealed means between 97 3
and 98.3% positive cells (SEM < 0 9).
Table 4. IL-2 response
Neonatally treated mice
Recipient
of lymphocytes
Cells injected
(Mls-1)
from neonatally tolerant BALB/c mice
Stimulators Response to: IL-2 (U/ml)
BALB/c
DBA/2
BALB/c
BALB/c
BALB/c
DBA/2
(a)
(C57BL/6 x BALB/c)F,
(b/b)
(C57BL/6 x DBA/2)F,
(b/a)
BALB.D2-MIS8
BALB/c
C57BL/6
B10.G
BALB.D2-MIS8
BALB/c
C57BL/6
B10.G
BALB.D2-MIS8
BALB/c
C57BL/6
B10.G
BALB D2-Mls"
BALB/c
C57BL/6
B10.G
BALB 02-Mls8
BALB/c
C57BU6
B10.G
Mls-1a
H-2b
H-2"
H-2b
H-2"
Mls-1a
H-2b
H ^
Mls-1a
H-2b
H-2"
Mls-1a
H-2b
H-2"
33.0
2.5
32.5
20.1
1.8
3.2
29.2
32.8
0.0
0.0
20.5
12.7
20.3
1.7
9.5
15.3
1.9
2.2
10.8
13.0
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
3.3
0.7
0.5
1.1
09
1.4
1 2
1.6
0.5
0.8
1.2
0.1
1.1
3.5
0.7
0.5
1.6
2.3
Spleen cefte (5 x 10s) from 2- to 3-week-old neonataly treated or control mice respectively were stimulated with 5 x 105 irradiated T cell-depleted spleen
cells in 96-well plates. Supernatants were harvested after 48 h and assayed for IL-2 content. Data are mean ± SEM of U IL-2/ml culture supernatant
of three individual mice and of triplicate cultures.
Neonatal tolerance to Mls-1a 131
molecules on Vj6+ T cell was observed in lymphocytes from
BALB/c mice neonatally treated with Mls-1a F, cells when
compared to those transfused with Mls-1b F, (data not shown).
Lymphohemopoietic chimerism in mice treated with H-2-
incompatible cells was between 6.9 and 17.2% donor H-2 class I-
expressing lymph node cells when analyzed in 2- or 3-week-old
mice and between 0.6 and 5.1% in 4- to 6-week-old mice (data
not shown). Furthermore, the degree of chimerism appeared to
be independent of Mls-1a expression by the neonatally injected
cells.
Finally, in control experiments Mls-1a heterozygous
(C57BL/6 x DBA/2)F, spleen cells were injected neonatally
into H-2-syngeneic (C57BL/6 x BALB/c)F, hosts. As expected,
this resulted in deletion of V ^ T cells (Table 3A). In conclusion,
Mls-1b mice neonatally treated with Mls-1a spleen cells efficiently
deleted V f l6+ T cells if H-2-compatible but not if
H-2-incompatible spleen cells were used.
Non-deleted V/>+ Tcells from BALB/c (Mls-1b) mice neonatally
treated with H-2-incompatible Mls-1" spleen cells neither
secreted IL-2 nor proliferated after Mis-1" stimulation in vitro
Since BALB/c mice neonatally transfused with (C57BL/6 x
DBA/2)F, Mls-1a spleen cells did not delete the majority of their
Vfi+ lymphocytes, the question arose whether these lympho-
cytes would respond to an Mls-1a stimulus in vitro. Analyses of
lymphocytes from 2- to 3-week-old neonatally treated BALB/c
mice revealed practically no proliferation (data not shown) and
very low levels of IL-2 secretion after Mls-1a stimulation in vitro
(Table 4). In contrast, control untreated mice or mice neonatally
treated with (C57BL/6 x BALB/c)F, Mls-1b spleen cells
responded strongly to BALB.D2-Mls-1a stimulator cells. This
latter response was Mls-1 "-specific since only background IL-2
levels were found upon stimulation with syngeneic BALB/c spleen
cells. All the responder populations tested were responsive to
third-party H-2-incompatible B10.G stimulator cells. As expected,
lymphocytes from DBA/2 (Mls-1a) mice or BALB/c mice
neonatally given H-2-compatible Mls-1a spleen cells (both lack-
ing Vfi+ cells due to clonal deletion) revealed only very low
levels of IL-2 secretion after Mls-1a stimulation in vitro. In
summary, these data show that Mls-1b mice neonatally treated
with H-2-semi-allogeneic Mls-1a F, spleen cells contained
substantial numbers of Ve6+ T cells, which were unresponsive
to Mls-1a stimulation in vitro. However, it has to be mentioned
that this Mls-1 "-specific in vitro unresponsiveness was only
observed in mice up to the age of 3 weeks; non-deleted V^6+
lymphocytes from neonatally tolerized mice 4 or more weeks old
expressed only slightly reduced or even normal IL-2 and
proliferative responses to Mls-1a in vitro (data not shown).
Anergic V^6+ T cells responded to Mls-1" in vitro by
blastogenesis and expression of IL-2 receptors but did not
proliferate unless IL-2 was added to the cultures
Lymphocytes from thymus or lymph nodes of BALB/c mice
neonatally transfused with (C57BL/6 x DBA/2)F, or
(C57BL/6 x BALB/c)F, spleen cells respectively were
comparable in size as indicated by their mean values of forward
light scatter (thymocytes: 23.0 ± 0.7 or 22.7 ± 1.0 respectively;
lymph node cells: 25.9 ± 0.3 or 27.0 ± 0.4 respectively). These
values were not significantly different from untreated or
syngeneically treated control mice (data not shown), suggesting
that no detectable in vivo blastogenesis of tolerogen-specific
T cells occurred. However, after 3 day in vitro stimulation with
irradiated T cell-depleted spleen cells, as described above
(without addition of growth factors), many cells enlarged. In
cultures stimulated with Mls-1" cells this subset of large lympho-
cytes contained - 4 0 % V^6+ cells (data not shown). Further-
more, up to 66% of lymphoblasts stained positive with the
IL-2R-specific mAb PC61.51 (41) after in vitro Mls-1a stimulation.
Similar observations were made in lymphocyte populations
containing responsive or anergic V ^ + T cells, indicating that
blastogenesis and expression of IL-2R (but not IL-2 secretion or
proliferation) of anergic VJo+ cells occurred after Mls-1" stimula-
tion in vitro.
Since functional anergy in some systems appears to reflect
defective IL-2 production (11,13-16), we further analyzed v^S
expression in cultures after addition of exogenous IL-2:
responding T cell blasts from 3 day MLRs were re-incubated in
IL-2-containing medium for an additional 2 days. As shown in
Table 5, responder populations from BALB/c mice, whether
untreated or neonatally treated with (C57BL/6 x DBA/2)F, or
(C57BL/6 x BALB/c)F, spleen cells, respectively, revealed an
increased proportion of V/56+/CD4+ cells (to -40%) following
Mls-1" stimulation. Since viable cell recoveries were - 10-fold
greater in response to Mls-1a than in syngeneic controls (Table
5), these data indicate that actual expansion (rather than
preferential survival) occurred. In contrast, no significant
expansion of the VS6+ subset was detected in CD4 +
lymphocytes from mice rendered tolerant to Mls-1" by clonal
deletion (i.e. DBA/2 mice or BALB/c mice neonatally treated with
DBA/2 spleen cells). In conclusion, non-deleted V ^ T cells
from BALB/c mice neonatally treated with (C57BL/6 x
DBA/2)F, Mls-1a spleen cells generated blasts and expressed
IL-2R after Mls-1a stimulation in vitro but were defective in IL-2
production and therefore apparently did not proliferate unless
exogenous IL-2 was added to the cultures.
In-vitro unresponsiveness of allospecific cytotoxic T cell
precursors but not of allospecific IL-2-secreting cells from BALB/c
mice neonatally treated with H-2bxd spleen cells
In MLRs such as described above, the response to donor
allogeneic (H-2b) stimulators was investigated in parallel. The
data in Table 4 show that lymphocytes from H-2d mice
neonatally treated with H-2tad spleen cells secreted significant
amounts of IL-2 after H-2b stimulation in vitro, although this
response was lower than the response of controls (untreated or
treated with H-2d spleen cells). In contrast, spleen cells from
BALB/c mice neonatally treated with H-2bxd F, spleen cells did
not give rise to H-2b-specific cytotoxic T lymphocytes (CTLs) in
standard mixed lymphocyte cultures, but generated CTLs specific
for third-party H-2" determinants (Table 6). Thus, neonatal
injection of semi-allogeneic spleen cells expressing foreign H-26
molecules rendered allospecific CTLs unresponsive but only
partially reduced allospecific IL-2 secretion. In conclusion,
tolerance induction to MHC determinants did not parallel Mls-1a
tolerance described above.
Discussion
Actively acquired tolerance to MHC-incompatible grafts can be
achieved by neonatal injection of the relevant histoincompatible
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Table 5. Mls-1a-specific in vitro proliferation of Vf l6+ cells from neonatally tolerant mice after addition of exogenous IL-2
Neonatally
Recipient
BALB/c
DBA/2
BALB/c
BALB/c
BALB/c
treated mice
Cell injected
(Mls-1)
—
DBA/2
(a)
(C57BL/6 x BALB/c)F,
(b/b)
(C57BL/6 x DBA/2)F,
(b/a)
Stimulators
before culture
BALB.D2Mlsa
(C57BL/6 x DBA/2)F,
BALB/c
before culture
BALB.D^Mte8
BALB/c
before culture
BALB.D2-MIS8
(C57BU6 x DBA/2)F,
BALB/c
before culture
BALB.D2-MIS8
(C57BL/6 x DBA/2)F,
BALB/c
before culture
BALB.D2-MIS8
(C57BL/6 x DBA/2)F,
BALB/c
Response to:
(Mls-18)
(Mls-1a/H-2b)
(Mls-I8)
(Mls-1a
(MIs-^/H^15)
(Mis-1s)
(Mls-I'VH^13)
(Mls-1a
(Mls-1 aIH-2^
Cells recovered
Relative
no.
(x10-5/ml)
15
ND
2.3
4.2
3.0
28
ND
2.5
176
ND
1 8
16.1
ND
1.5
%V"6+/CD4 +
12 8 ± 0.7
40.8 ± 0.9
27.6 ± 4.0
7.2 ± 3.9
CO
 
CO
 
CO
A 
A
 
A
 
A
CO
 
CO
 
CO
 
CO
12 3 ± 0.9
40 5 ± 5.2
26.7 ± 5 6
9 1 ± 0.2
9.6 ± 0.7
37.2 ± 1 6
31.4 ± 3 1
4.4 ± 2 0
Spleen cells (3x10* ) from 2- to 3-week-old neonataly treated or control mice respectively were stimulated with 5 x 106 irradiated T cell-depleted spleen
cells in 24-well plates. After 3 days, cells were harvested, washed, and re-cultured for an additional 48 h in IL-2-containing medium. Recovered cells
were counted and double-stained with V^6 and CD4-specific mAbs Measurements are given as percentages of the total CD4+ cells. The cultures
stimulated with BALB.D2-MIS8 contained < 3 % H-2b+ cells (mAb K7-309) and between 45 and 55% IL-2R+ cells (mAb PC61.51) with the exception
of the cultures with responder lymphocytes from untreated DBA/2 mice or BALB/c mice treated with DBA/2 cells where <17% cells were IL-2R +
Data are mean (±SEM) of three mice per group. SEM of numbers of recovered cells ranged between 0.8 and 2 8. ND, not done
Table 6. Allo-H-2-specific cytotoxic T cell response of neonatally tolerant BALB/c mice
Neonatally treated mice
Recipient
BALB/c
DBA/2
BALB/c
BALB/c
BALB/c
BALB/c
Cells injected
_
-
(C57BL/6 x BALB/c)F1
(C57BU6 x BALB/c)F,
(C57BL/6 x DBA/2)F,
(C57BU6 x DBA/2)F,
% specific lysis of target
B10.D2 (H-2d)
0/1/0/0
22/17/5/2
0/0/0/0
0/0/0/9
22/7/2/0
2/5/8/2
cells (E:T ratio 25/8/2.5/0.8)
MC57G (H-213)
78/56/29/7
91/91/58/23
0/0/0/0
6/0/0/0
0/0/0/0
0/0/0/0
DBA/1 (H-2")
62/42/23/9
73/57/32/18
81/72/56/19
83/69/62/18
84/62/34/14
83/52/34/17
Representative data for two expenments with effector spleen cells from six individual neonatally treated or control mice are shown. Spleen cells (3 x 106)
were stimulated in 24-well plates with 5 x 106 irradiated (2000 rad) spleen cells of BALB/c (H-2<i), C57BL/6 (H-2b), or DBA/1 (H-2^ mice respectively,
according to the H-2 haplotype of the target fibroblasts. After 5 days, cells were harvested and tested in a 51Cr-release assay Test duration was 4.5 h;
spontaneous 51Cr-release of target cells was <25%. E:T ratio, effectontarget ratio.
lymphoid cells (27). More recently, the same protocol has been
used to induce specific functional tolerance to Mls-1a
determinants (42,43). With the realization that T cell reactivity to
Mls-1a correlates with usage of particular Vp segments (3,4), it
has now become possible to investigate directly whether neonatal
tolerance to Mls-1a is obligatorily associated with clonal deletion
of the relevant Mls-1a-specific T cells. We show here that
neonatal tolerance to Mls-1a may be accomplished by either
clonal deletion or clonal unresponsiveness, depending on the
MHC molecules co-expressed on the injected cells. Thus,
neonatal injection of MHC-compatible Mls-1a-bearing cells
results in virtually complete clonal deletion, in agreement with
earlier reports (28,44). In contrast, inoculation of MHC-
incompatibJe cells expressing Mls-1a does not lead to efficient
donal deletion but, rather, causes a transient non-responsiveness
of T cells to Mls-1a determinants in vitro.
In this latter case, where H-2 semi-allogeneic Mls-1a spleen
cells were injected in neonatal mice, it could be argued that only
Vfi + T cells with low affinity/avidity for Mls-1a have survived.
However, because Mls-1 "-specific blastogenesis and IL-2R
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expression were inducible in the otherwise unresponsive V^6 +
lymphocytes, it appears that their TCR affinity was sufficient for
Mls-1a-specific interactions. Therefore it seems likely that the
neonatal injection of H-2 semi-allogeneic Mls-1a spleen cells
induced a state of clonal anergy in host Ve6+ cells.
Previous studies indicated that antigen-specific clonal paralysis
may be induced in vivo in adult mice by injection of chemically
fixed accessory cells (10) or MHC class ll-bearing L cell trans-
fectants (45). Anergy of Vp6+ T cells to Mls-1a was subsequently
demonstrated directly by Qin et al. (12), who showed specific
in vitro unresponsiveness of V/36+ lymphocytes from adult mice
after in vivo treatment with T cell-specific mAbs plus Mls-1a-
bearing hemopoietic cells. Similarly, Rammensee ef al. (13)
described in vitro anergic Vp6 + cells from adult Mls-1b mice after
in vivo immunization with Mls-1a spleen cells. Furthermore,
in vitro unresponsive Vg6+ T cells were observed in irradiated
Mls-1a mice reconstituted with certain (I -E~) bone marrow stem
cells (14-16). Mechanisms of T cell unresponsiveness in these
models may be similar to the neonatally treated mice described
in this study. The generation of antigen-specific blasts expressing
IL-2R in the absence of IL-2 secretion and proliferation are
common features of these systems (11,13-16) However, the
cellular and molecular interactions responsible for this anergic
state remain to be elucidated (11).
The limited data on MHC tolerance obtained in this study do
not allow detailed conclusions except that there was no direct
correlation with Mls-1a tolerance. The differential induction of
allospecific functional tolerance in CTLs (presumably MHC dass
l-specific) but not in IL-2 producers (presumably MHC class II-
spedfic) observed in mice treated neonatally with semi-allogeneic
spleen cells is consistent with some examples of split tolerance
(43,46), whereas other studies revealed successful neonatal
tolerance induction to both allogeneic MHC class I and II
determinants (47,48). In any event, interpretation of split tderance
is difficult since allogeneic MHC responses do not correlate with
usage of particular TCR Vfl segments and hence lack of
responsiveness (as observed for MHC class I) may result from
clonal deletion, clonal anergy, or other unspecified mechanisms.
It has been suggested that neonatal tolerance depends upon
persistence of antigen in vivo (49,50). Our evidence that
peripheral lymphocytes of neonatally treated mice contained
~ 10% donor MHC class l-expressing cells when analyzed after
2 weeks and still - 3 % of such cells when tested at the age of
5 weeks may indicate long-lasting persistence of neonatally
administered MHC class l-expressing cells. Unfortunately,
persistence of donor Mls-1a expressing cells is more difficult to
monitor in vivo and it is possible that such cells may have been
rejected more rapidly, thus causing the observed transient
tolerance to Mls-1a.
In conclusion, the present results emphasize the complexity
inherent in establishing neonatal T cell tolerance to foreign
Mls-1a and MHC determinants. Nevertheless, the availabiltiy of
a model system in which several distinct tderogenic mechanisms
(i.e. donal deletion and clonal anergy) operate for a single antigen
(Mls-1a) should facilitate further experimentation.
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